Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-06-08

FDA Approved: AMBRISENTAN — Supplemental Application (Sigmapharm Laboratories, LLC)

View source ↗

Summary

FDA approved a supplemental application for a generic version of ambrisentan (AMBRISENTAN) from Sigmapharm Laboratories, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)